To continue to make progress in Pediatric Oncology-Hematology (POH), we need to perpetuate the pool of talented and trained POH physician-scientists and PhD scientists who will make POH-relevant discoveries and provide investigative leadership. This has become ever more challenging in the field of POH, as there continues to be a shortage of young investigators with extensive laboratory research expertise. Fortunately, we are able to attract candidates willing to spend the time in the laboratory until the tutelage of outstanding investigators who are able to inculcate them with the culture of research that predominates at JHMI and the NCI, despite the current challenging funding climate. This grant and the philanthropic funds that we raise enables us to guarantee them at least 3 years in the laboratory, with many staying on at the Instructor level for additional time until they are fully ready to establish their own lab. In the current funding period (2012-2017), this grant has already supported superb laboratory research training for an outstanding group of 23 physician-scientists and 5 PhD scientists who have demonstrated a high degree of productivity and commitment to careers in cancer research. In addition, these trainees have strengthened the laboratory research base in POH in the Johns Hopkins Medical Institutions (JHMI) and the POB of the NCI. This application seeks support for 10 interdisciplinary postdoctoral research fellowship positions to fund the research training that is the major ingredient of the combined Johns Hopkins University/National Cancer Institute (NCI) Subspecialty Fellowship Training Program in POH (Joint Fellowship). We previously had 10 funded positions which were reduced to 8 because of NCI budgetary considerations despite a perfect score during the last renewal. This forced us to reduce the number of starting trainees in the Joint Fellowship training program from 7 to 6. Returning to 10 training slots will allow our program to provide sufficient duration of mentored research for the physician-scientists that will become leaders in the field. Two groups of postdoctoral fellows will be supported by the grant proposed herein. The major group of trainees will be composed of physician-scientists, since the laboratory research training of academic POH physician- scientists is the primary objective of this training program. These highly selected physician-scientists will have completed the clinical year of their fellowships in the Joint Fellowship. The second (smaller) group of trainees will be composed of PhD postdoctoral scientists working at JHMI on projects highly relevant to the biology of childhood cancer and blood diseases. These strongly qualified trainees will be provided intensive 3-year research experiences that will prepare them for careers in cancer research. Trainees work on projects relevant to the biology of childhood cancer and blood diseases, in the laboratories of leading scientists. The trainees and their mentors participate in an interactive, dynamic research environment bridging the JHMI and the NIH, with an emphasis on translational research.

Public Health Relevance

Summary of relevance to public health: This program provides postdoctoral education, training, and experience in field-leading research on childhood cancer and blood diseases, principally for physician-scientist trainees during their subspecialty fellowship in pediatric oncology-hematology. It ensures that a pipeline of well-trained physician-scientists can continue the progress that has been made in the treatment of these life-threatening diseases affecting children.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA060441-26
Application #
9570225
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Perkins, Susan N
Project Start
1993-09-30
Project End
2023-07-31
Budget Start
2018-08-02
Budget End
2019-07-31
Support Year
26
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Guo, Hong; Barberi, Theresa; Suresh, Rahul et al. (2018) Progression from the Common Lymphoid Progenitor to B/Myeloid PreproB and ProB Precursors during B Lymphopoiesis Requires C/EBP?. J Immunol 201:1692-1704
Martin, Allison M; Nirschl, Christopher J; Polanczyk, Magda J et al. (2018) PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget 9:19177-19191
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Lemberg, Kathryn M; Vornov, James J; Rais, Rana et al. (2018) We're Not ""DON"" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine. Mol Cancer Ther 17:1824-1832
Kim, Jennifer E; Patel, Mira A; Mangraviti, Antonella et al. (2017) Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res 23:124-136
Miyahara, Hiroaki; Yadavilli, Sridevi; Natsumeda, Manabu et al. (2017) The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett 400:110-116
Rubens, Jeffrey A; Wang, Sabrina Z; Price, Antoinette et al. (2017) The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. Neuro Oncol 19:1361-1371
Yang, Yinmeng; Kohler, M Eric; Chien, Christopher D et al. (2017) TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med 9:
Rabik, Cara A; Atkinson, Meredith A; Sule, Sangeeta et al. (2017) Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure. Transfusion 57:2159-2163
Gryder, Berkley E; Yohe, Marielle E; Chou, Hsien-Chao et al. (2017) PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discov 7:884-899

Showing the most recent 10 out of 108 publications